Print
Email
Print Edition StoriesThursday, September 3, 2009
Thermo Fisher acquires German diagnostics firm
By Mass High Tech staff
MHT's Julie Donnelly: Life science startups finding investments
Breaking down the MIT $100K
Innerscope Research sensor vest tests biometric response to visual aids
Thermo Fisher Scientific Inc., the Waltham-based instrumentation and research products company, has signed a deal to buy in-vitro diagnostics test firm BRAHMS AG for about $470 million. BRAHMS is a German company, with European and U.S. sales offices, that employs 400 people. Upon completion of the acquisition, expected this month, the company will become part of the Specialty Diagnostics unit of Thermo Fisher’s Analytical Technologies Segment.
BRAHMS develops a diagnostic biomarker, called Procalcitonin (PCT), that detects and monitors the treatment of sepsis, a condition of bacterial infestion overtaking a person’s bloodstream.
In April, Waltham-based Thermo Fisher Scientific (NYSE: TMO) announced an agreement to pay about $120 million to buy Biolab Pty. Ltd., the scientific and medical division of Alesco Corp., an industrial brands company in Australia and New Zealand. Biolab develops laboratory equipment, analytical instruments and life science consumables.
The company reported a net profit of $994 million on total revenue of $10.5 billion in 2008, compared to a net profit of $761 million on $9.75 billion in 2007.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
